Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule

Executive Summary

FDA will use its authority to require risk evaluation and mitigation strategies judiciously, according to Chief Medical Officer and CDER Acting Director Janet Woodcock

You may also be interested in...



FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff

FDA's Office of Surveillance and Epidemiology is again undergoing changes as the agency continues to strengthen its drug safety operations. OSE is reorganizing prior to increasing staff by 50 percent to undertake new regulatory authorities

Clinical Trial Certification Requirements Under FDAAA May Be “Time Bomb”

The section of the FDA Amendments Act that requires companies to post information about their clinical trials contains a "hidden time bomb," according to I. Scott Bass, a partner at the law firm Sidley Austin

FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff

FDA's Office of Surveillance and Epidemiology is again undergoing changes as the agency continues to strengthen its drug safety operations. OSE is reorganizing prior to increasing staff by 50 percent to undertake new regulatory authorities

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel